, Tracking Stock Market Picks
Enter Symbol:
Glaxosmithkline Plc (GSK) [hlAlert]

down 25.26 %

Glaxosmithkline Plc (GSK) rated Buy with price target $48 by Argus

Posted on: Monday,  Dec 7, 2015  8:25 AM ET by Argus

Argus rated Buy Glaxosmithkline Plc (NYSE: GSK) on 12/07/2015. Previously Argus rated Buy Glaxosmithkline Plc (NYSE: GSK) on 04/23/2014., when
the stock price was $55.14. Since then, Glaxosmithkline Plc has lost 25.26% as of 12/07/2015's recent price of $41.21.
If you would have followed the previous Argus's recommendation on GSK, you would have lost 25.26% of your investment in 593 days.

GlaxoSmithKline plc (GSK) is a global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK?s principal pharmaceutical products include medicines in the therapeutic areas, such as respiratory, central nervous system, anti-virals, anti-bacterials, metabolic, vaccines, cardiovascular and urogenital, oncology and emesis. It has operations in some 114 countries and products sold in over 150 countries. The Company operates in two segments: Pharmaceuticals (prescription pharmaceuticals and vaccines) and Consumer Healthcare. On October 14, 2008, it acquired the Egyptian mature products business of Bristol Myers Squibb Company (BMS). In July 2009, BMS' branded generics business, which comprises a portfolio of 13 branded pharmaceuticals was acquired by the Company. In July 2009, GSK acquired Stiefel Laboratories, Inc.

Argus Research is an independent research firm, and our business is producing, distributing and marketing high-quality investment and economic research. Our recommendations - BUY, HOLD and SELL - reflect the judgment of an analyst about a company's prospects as an investment in terms of value, expected growth and risks. Argus Research does not bring companies public, advise companies on mergers and acquisitions, broker trades, make markets in stocks or manage money. Our independence allows us to make critical judgments about companies that we might not be so free to make were we competing for a firm's underwriting business. Because we're not a broker/dealer, we don't have "inventory" of a stock that we have to move with a tainted recommendation. We have developed a six-point system for analyzing the stocks in our Universe of Coverage. We believe that this system
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/7/2015 8:25 AM Buy
40.23 48.00
as of 8/27/2015
1 Week down  -3.51 %
1 Month down  -5.00 %
3 Months down  -8.40 %
1 YTD down  -25.26 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/23/2014 12:00 AM Buy

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy